



Ref: IIL/SE/2026/2805/01

Date: May 28, 2026

The Manager

| | |
|--|--|
| Listing Compliance Department BSE Limited (Through BSE Listing Centre) Scrip Code: 532851 | Listing Compliance Department National Stock Exchange of India Limited (Through NEAPS) Symbol: INSECTICID |
|--|--|

Dear Sir/Madam,

Re: Outcome of the Board Meeting

This has reference to our letter no.: IIL/SE/2026/1604/01 dated April 16, 2026.

The Board of Directors of the Insecticides (India) Limited, at their meeting held today i.e May 28, 2026 has *inter alia* considered and approved the following(s):

Financial Results:

1. Considered and approved the Audited Financial Results of the Company, for the Quarter and Year ended March 31, 2026 along with Auditor's Report based upon unmodified opinion of M/s S S Kothari Mehta & Co., LLP and M/s Devesh Parekh & Co., Joint Statutory Auditor(s) of the Company. The Financial Results were reviewed and recommended by the Audit Committee. Accordingly, we enclosed the following as **Annexure I:**
 - a. Audited financial results for the financial year ended March 31, 2026.
 - b. Auditor's Report issued on the Financial Results.
 - c. A Declaration pursuant to Regulation 33(3) of the SEBI Listing Regulations, regarding unmodified opinion of the Statutory Auditors on the Financial Results.

A copy of the said results together with the Auditor's report are also being made available on the website of the Company at www.insecticidesindia.com.

Formulation of Employee Stock Purchase Scheme 2026 ("IIL ESPS Scheme 2026 or Scheme"):

2. On the recommendation of the Nomination Remuneration and Ethics Committee, the Board of Directors approved the formulation of Employee Stock Purchase scheme 2026. The aggregate number of ESPS that may be offered, issued and allotted under the Scheme shall not exceed 2,00,000 (Two Lakhs) Equity Shares (or such other adjusted figure for



any bonus, stock splits or consolidations or other reorganization of the capital structure of the Company as may be applicable from time to time) of face value of Rs. 10/- each. The Equity Shares to be issued and allotted under this Scheme shall remain Lock in for a period of 1 (One) year from the date of allotment and also available to the employee of Subsidiary Companies of the Insecticides (India) Limited.

The Scheme shall be administered by the Nomination Remuneration and Ethics Committee (“NRC Committee”) designated as Compensation Committee and shall be subject to the shareholders’ approval at the ensuing 29th Annual General Meeting (AGM). The details required as per SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 will form part of the explanatory statement to the notice of the AGM of the Company.

The details of the Scheme, as required in respect of the above under Regulation 30 read with Schedule III of the Listing Regulations read with SEBI master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given under **Annexure-II**.

Resignations and Appointments

3. Take note of resignation of Mrs. Nikunj Aggarwal (DIN: 06569091) as Whole Time Director of the Company with immediate effect. She confirmed that there is no other material reason for resignation other than those mentioned in her resignation letter.

The requisite disclosure as required as per Regulation 30 read with clause 7C of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2 / I/3762/2026 dated January 30, 2026 along with the resignation letter of Mrs. Nikunj Aggarwal is annexed herewith as **Annexure III**.

4. On the recommendation of the Nomination Remuneration and Ethics Committee, the Board of Directors approved the appointment of Mr. Sanskar Aggarwal (DIN: 09675297) as an Whole Time Director (Additional) of the Company for a term of five consecutive years effective from May 28, 2026 till May 27, 2031 (both days inclusive), liable to retire by rotation and as an Director (Additional) in Kaeros Research Limited - *formerly known as Kaeros Research Private Limited* (a Wholly owned subsidiary) with effective from May 28, 2026. The said appointment(s) are subject to the approval of the Shareholders of the Company in the ensuing Annual General Meeting of the Company and its Subsidiary.

Mr. Sanskar Aggarwal (DIN: 09675297) is not disqualified from being appointed as a Whole-time Director (Additional) in terms of the Companies Act 2013 and has given his consent to act as a Whole-time Director.



Azadpur Commercial Complex, Delhi - 110 033
Telefax : + 91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



Further, as required by Circular no. NSE/CML/2018/02 dated June 20, 2018, issued by NSE and Circular no. LIST/COMP/14/2018-19 dated June 20, 2018 issued by BSE, he is not debarred from holding the office of a director by virtue of any SEBI order or any other Authority.

5. On the recommendation of the Nomination Remuneration and Ethics Committee, the Board of Directors approved the appointment of Mr. Atul Kumar as a Vice President- Sales (North), a Senior Management Personnel (SMP) of the Company w.e.f May 28, 2026.

Brief profile and other details w.r.t Business item no. 4&5 above as required under regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2 / I/3762/2026 dated January 30, 2026 are enclosed as **Annexure IV**.

6. On the recommendation of the Audit Committee, the Board of Directors has approved the appointment of M/s. T Jain & Associates, Chartered Accountants (FRN:017110C) as an Internal Auditor of the Company for a period of five years effective from April 01, 2026 till March 31, 2031.

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2 / I/3762/2026 dated January 30, 2026, is enclosed as **Annexure V**.

Annual General Meeting

7. The 29th Annual General Meeting (AGM) of the Company will be held on Wednesday, August 12, 2026 at 03:00 PM through Video Conferencing ("VC").

The Board meeting commenced at 01:00 PM (IST) and concluded at 04:15 PM (IST)

You are requested to kindly take on records.

Thanking You,
For Insecticides (India) Limited

(Sandeep Kumar)
Company Secretary & CCO

Encl: As above

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;

Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ In lacs, except EPS)

| Sl No. | Particulars | Quarter Ended | | | Year Ended | |
|--------|---|-------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
| | | 31-03-2026 (Audited) | 31-12-2025 (Unaudited) | 31-03-2025 (Audited) | 31-03-2026 (Audited) | 31-03-2025 (Audited) |
| I | Revenue from operations | 42,795.60 | 38,356.38 | 35,914.51 | 2,14,414.11 | 2,00,226.58 |
| II | Other Income | 480.29 | 88.88 | 293.54 | 1,211.12 | 722.58 |
| III | Total Income (I+II) | 43,275.89 | 38,445.26 | 36,208.05 | 2,15,625.23 | 2,00,949.16 |
| IV | Expenses | | | | | |
| | (a) Cost of materials consumed | 26,829.00 | 22,181.04 | 32,731.06 | 1,24,564.76 | 1,35,514.02 |
| | (b) Purchase of Stock-in-Trade | 3,139.60 | 2,346.48 | 1,219.55 | 13,290.04 | 7,511.27 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 110.06 | 1,735.52 | (11,099.52) | 10,375.48 | (6,389.16) |
| | (d) Employee benefits expense | 3,641.99 | 3,542.80 | 2,815.28 | 15,984.90 | 13,715.70 |
| | (e) Finance costs | 418.05 | 460.60 | 201.77 | 1,651.20 | 672.32 |
| | (f) Depreciation and amortization expense | 932.43 | 934.34 | 713.62 | 3,521.60 | 2,904.75 |
| | (g) Other expenses | 6,334.52 | 6,021.07 | 7,401.16 | 28,039.55 | 27,991.77 |
| | Total expenses | 41,405.65 | 37,221.85 | 33,982.92 | 1,97,427.53 | 1,81,920.67 |
| V | Profit before tax (III-IV) | 1,870.24 | 1,223.41 | 2,225.13 | 18,197.70 | 19,028.49 |
| VI | Tax Expense | | | | | |
| | (1) Current Tax | 76.56 | 407.38 | 1,222.43 | 4,224.13 | 5,539.15 |
| | (2) Deferred Tax | 357.31 | (68.27) | (399.79) | 391.83 | (487.22) |
| | Total Tax Expense | 433.87 | 339.11 | 822.64 | 4,615.96 | 5,051.93 |
| VII | Profit for the period/year (V-VI) | 1,436.37 | 884.30 | 1,402.49 | 13,581.74 | 13,976.56 |
| VIII | Other comprehensive income | | | | | |
| | Items that will not be reclassified to profit or loss | | | | | |
| | (i) Changes in fair value of FVTOCI equity instruments | 328.87 | (163.38) | 31.26 | 407.98 | (30.71) |
| | (ii) Remeasurement of net defined benefit plans | (17.11) | (35.00) | (135.77) | (122.11) | (139.52) |
| | (iii) Income tax relating to these items | (72.31) | 46.87 | 26.88 | (64.31) | 42.26 |
| | Other comprehensive income for the period/ year (net of tax) | 239.45 | (151.51) | (77.63) | 221.56 | (127.97) |
| IX | Total comprehensive income for the period/ year (VII+VIII) | 1,675.82 | 732.79 | 1,324.86 | 13,803.30 | 13,848.59 |
| | Paid up equity share capital (Face value ₹10/- each) | 2,909.78 | 2,909.78 | 2,909.78 | 2,909.78 | 2,909.78 |
| | Other Equity | - | - | - | 1,18,490.59 | 1,05,269.25 |
| | Earnings per share (of ₹10 each) | | | | | |
| | (a) Basic | 4.94 | 3.04 | 4.82 | 46.68 | 47.61 |
| | (b) Diluted | 4.94 | 3.04 | 4.82 | 46.68 | 47.61 |
| | (Note: EPS for respective quarters are not annualized) | | | | | |

Notes:

- The above Audited Standalone Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 28, 2026. The auditors of the company have carried out the audit of the same. The Audit Report along with Financial Results for the quarter and year ended March 31, 2026 are available on the Stock Exchanges website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com.
- The above Audited Standalone Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.



R. Gul

- 3 The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
- 4 The Board of Directors of Insecticides (India) Limited in its meeting held on August 09, 2024 had approved the dissolution/ liquidation of its wholly owned subsidiary IIL Overseas DMCC, Dubai. IIL Overseas DMCC has filled the windup/ dissolution with DMCCA (Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority) and dissolution is approved vide its letter dated September 19, 2025.
- 5 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21, 2025. The corresponding all supporting rules under these codes are yet to be notified.

The Company has estimated that there is no incremental liability due to implications of these laws to the standalone financial statements.

Further, the Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

- 6 The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year up to 31 March 2026 and the unaudited published year-to-date figures up to 31 December 2025 being the date of the end of the third quarter of the financial year which were subjected to a limited review.

For and on behalf of the Board




Rajesh Kumar Aggarwal
Managing Director
CIN : 00576872

Place: Delhi

Date: May 28, 2026

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF AUDITED STANDALONE BALANCE SHEET AS AT MARCH 31, 2026

| | | (₹ In lacs) | |
|-------|--|--------------------|--------------------|
| S. No | Particulars | As at 31-03-2026 | As at 31-03-2025 |
| | ASSETS | | |
| (1) | Non-current assets | | |
| (a) | Property, plant and equipment | 30,928.77 | 22,981.29 |
| (b) | Capital work-in-progress | 11,844.88 | 15,599.24 |
| (c) | Investment properties | 99.87 | 104.67 |
| (d) | Right-of-use assets | 4,614.76 | 3,904.01 |
| (e) | Other Intangible assets | 793.81 | 852.75 |
| (f) | Intangible assets under development | 1,108.48 | 498.54 |
| (g) | Investment in subsidiaries and jointly controlled entity | 1,819.27 | 1,823.56 |
| (h) | Financial assets | | |
| (i) | Investments | 1,230.16 | 822.18 |
| (ii) | Other financial assets | 429.23 | 267.32 |
| (i) | Income tax assets (net) | 477.40 | 132.72 |
| (j) | Other non-current assets | 1,960.78 | 604.65 |
| | Total non-current assets | 55,307.41 | 47,590.93 |
| (2) | Current assets | | |
| (a) | Inventories | 76,831.32 | 88,268.01 |
| (b) | Financial assets | | |
| (i) | Trade receivables | 48,949.61 | 38,567.91 |
| (ii) | Cash and cash equivalents | 8,712.51 | 5,538.01 |
| (iii) | Bank balances other than (ii) above | 16.77 | 118.11 |
| (iv) | Loans | 26.87 | 25.01 |
| (v) | Other financial assets | 1,318.15 | 851.47 |
| (c) | Other current assets | 7,379.82 | 7,800.52 |
| | Total current assets | 1,43,235.05 | 1,41,169.04 |
| | Total assets | 1,98,542.46 | 1,88,759.97 |
| | EQUITY AND LIABILITIES | | |
| | EQUITY | | |
| (a) | Equity share capital | 2,909.78 | 2,909.78 |
| (b) | Other equity | 1,18,490.59 | 1,05,269.25 |
| | Total equity | 1,21,400.37 | 1,08,179.03 |
| | LIABILITIES | | |
| (1) | Non-current liabilities | | |
| (a) | Financial liabilities | | |
| (i) | Borrowings | 1,798.34 | 2,347.24 |
| (ii) | Lease liabilities | 887.82 | 264.60 |
| (b) | Provisions | 288.59 | 544.60 |
| (c) | Deferred tax liabilities (Net) | 942.78 | 486.63 |
| | Total non-current liabilities | 3,917.53 | 3,643.07 |
| | Current liabilities | | |
| (2) | (a) Financial liabilities | | |
| (i) | Borrowings | 12,092.38 | 7,551.74 |
| (ii) | Lease liabilities | 365.41 | 239.54 |
| (iii) | Trade Payables | | |
| (A) | total outstanding due of micro enterprises and small enterprises; and | 6,918.58 | 2,250.29 |
| (B) | total outstanding dues of creditors other than micro enterprises and small enterprises | 37,075.43 | 47,777.29 |
| (iv) | Other financial liabilities | 4,338.56 | 4,699.45 |
| (b) | Other current liabilities | 12,016.05 | 13,055.91 |
| (c) | Provisions | 418.15 | 483.59 |
| (d) | Current tax liabilities (Net) | - | 880.06 |
| | Total current liabilities | 73,224.56 | 76,937.87 |
| | Total equity and liabilities | 1,98,542.46 | 1,88,759.97 |

For and on behalf of the Board of Directors
Insecticides (India) Limited



Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Place: Delhi
Date: May 28, 2026

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;

Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

AUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

(₹ In lacs)

| Particulars | 31-03-2026 | 31-03-2025 |
|---|-------------------|-------------------|
| (A) Cash Flow From Operating Activities | | |
| Profit before tax | 18,197.70 | 19,028.49 |
| Adjustment on account of | | |
| - Depreciation | 3,521.60 | 2,904.75 |
| - (Profit)/ Loss on sale of property, plant & equipment | (44.09) | (19.09) |
| - Net gain on lease modification | (1.56) | - |
| - Interest income | (26.08) | (235.45) |
| - Dividend income | (26.00) | (22.83) |
| - Interest expenses | 1,651.20 | 672.32 |
| - Bad debts written off | 2.85 | 29.26 |
| - Loss Allowance on Advances | 0.17 | 217.83 |
| - Impairment expenses on investment | - | 6.84 |
| - Provision for impairment of trade receivables | 446.75 | 554.65 |
| - Derivative (gain) / loss | (845.87) | 305.42 |
| - Unrealised exchange differences | 318.16 | (290.12) |
| Operating Profit Before Working Capital Changes | 23,194.83 | 23,152.07 |
| Adjustments for | | |
| - (Increase)/Decrease in security deposits | (49.68) | (30.54) |
| - (Increase)/Decrease in inventories | 11,436.69 | (7,621.98) |
| - (Increase)/Decrease in trade receivables | (10,342.99) | (9,434.30) |
| - (Increase)/Decrease in loans | (1.86) | (10.62) |
| - (Increase)/Decrease in other financial assets | 174.09 | (763.76) |
| - (Increase)/Decrease in other current/ non-current assets | 431.26 | 400.55 |
| - Increase/(Decrease) in provisions | (443.56) | 259.04 |
| - Increase/(Decrease) in trade payables | (6,667.91) | 8,471.01 |
| - Increase/(Decrease) in other financial liabilities | (369.74) | 356.62 |
| - Increase/(Decrease) in other current liabilities | (1,039.85) | (1,207.97) |
| Cash generated from operations | 16,321.28 | 13,570.12 |
| Less: Income tax paid | (5,448.87) | (4,107.96) |
| Net cash flow (used in) / from operating activities (A) | 10,872.41 | 9,462.16 |
| (B) Cash Flow From Investing Activities | | |
| - Purchase of property, plant and equipment and intangible assets, capital-work-in-progress and intangible assets under development | (9,274.38) | (3,568.61) |
| - Proceeds from sale of property plant and equipment | 203.46 | 261.87 |
| - Interest received | 26.08 | 235.45 |
| - Proceeds from / (investment in) bank deposits (net) | (10.89) | 2.32 |
| - Dividends received | 34.42 | 22.18 |
| - Investment in equity shares of subsidiary company | 4.29 | (824.27) |
| Net cash flow (used in) / from Investing Activities (B) | (9,017.02) | (3,871.06) |
| (C) Cash Flow From Financing Activities | | |
| - Repayment due to Buyback of equity shares including premium, expenses & taxes | - | (6,188.02) |
| - Repayment of non-current borrowings | (1,319.09) | (1,331.12) |
| - Proceeds from non-current borrowings | 676.14 | 708.59 |
| - Proceeds/(Repayment) from/of current borrowings | 4,462.57 | 2,149.01 |
| - Payment of lease liabilities | (271.78) | (220.41) |
| - Interest paid | (1,646.77) | (684.45) |
| - Dividend paid (Final & Interim) | (581.96) | (591.96) |
| Net cash flow (used in) / from financing activities (C) | 1,319.11 | (6,158.36) |
| Net increase/ (decrease) in Cash and Cash Equivalents (A+B+C) | 3,174.50 | (567.26) |
| Cash and Cash Equivalents at the beginning of the year | 5,538.01 | 6,105.27 |
| Cash and Cash Equivalents at the end of the year | 8,712.51 | 5,538.01 |

For and on behalf of the Board of Directors
Insecticides (India) Limited



Rajesh
Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Place: Delhi

Date: May 28, 2026

Independent Auditor's Report on the Quarterly and Year ended Audited Standalone Financial Results of Insecticides (India) Limited Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

**To The Board of Directors of
Insecticides (India) Limited**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of **Insecticides (India) Limited** (the "Company") for the quarter and year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income/(loss) and other financial information of the Company for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Managements and those charge with governance for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation of the Statement that give a true and fair view of the net profit and other comprehensive income/(loss) and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are



reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial control with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



**S S KOTHARI MEHTA
& CO. LLP**

Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi - 110020

DEVESH PAREKH & CO.

Chartered Accountants
675, Aggarwal Cyber Plaza-2,
Netaji Subhash Place, Pitampura, Delh 110034

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2026, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year -to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For S S Kothari Mehta & Co. LLP

Chartered Accountants

Firm's registration number: 000756N/N500441



Vijay Kumar

Partner

Membership number: 092671

UDIN : 26092671GKVODY7145

Place: Delhi

Date : May 28, 2026

For Devesh Parekh & Co.

Chartered Accountants

Firm's registration number: 013338N



Meenakshi

Partner

Membership number: 527873

UDIN:26527873KSDVEEC8040

Place: Delhi

Date : May 28, 2026

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ In lacs, except EPS)

| Sl No. | Particulars | Quarter Ended | | | Year Ended | |
|--------|--|-------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
| | | 31-03-2026 (Audited) | 31-12-2025 (Unaudited) | 31-03-2025 (Audited) | 31-03-2026 (Audited) | 31-03-2025 (Audited) |
| I | Revenue from operations | 42,625.96 | 38,491.62 | 35,892.05 | 2,14,000.98 | 1,99,994.96 |
| II | Other Income | 473.19 | 76.25 | 285.55 | 1,170.88 | 699.55 |
| III | Total Income (I+II) | 43,099.15 | 38,567.87 | 36,177.60 | 2,15,171.86 | 2,00,694.51 |
| IV | Expenses | | | | | |
| | (a) Cost of materials consumed | 24,666.46 | 21,762.46 | 32,637.84 | 1,20,019.64 | 1,34,837.66 |
| | (b) Purchase of Stock-in-Trade | 5,156.55 | 1,506.46 | 1,219.55 | 16,957.82 | 7,511.27 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (83.68) | 2,738.12 | (11,101.14) | 9,515.37 | (6,436.78) |
| | (d) Employee benefits expense | 3,799.03 | 3,645.57 | 2,863.47 | 16,374.48 | 13,870.97 |
| | (e) Finance costs | 431.96 | 468.18 | 214.09 | 1,687.93 | 686.45 |
| | (f) Depreciation and amortization expense | 944.09 | 941.23 | 717.04 | 3,549.59 | 2,915.34 |
| | (g) Other expenses | 6,528.01 | 6,100.06 | 7,424.84 | 28,428.84 | 28,090.11 |
| | Total expenses | 41,442.42 | 37,162.08 | 33,975.69 | 1,96,533.67 | 1,81,475.02 |
| V | Profit before tax, exceptional items and share of net profit of investment accounted for using equity method (III-IV) | 1,656.73 | 1,405.79 | 2,201.91 | 18,638.19 | 19,219.49 |
| VI | Share of net profit of jointly controlled entity accounted for using the equity method | (50.12) | 24.47 | 0.42 | 29.74 | 57.45 |
| VII | Profit Before Tax (V+VI) | 1,606.61 | 1,430.26 | 2,202.33 | 18,667.93 | 19,276.94 |
| VIII | Tax Expense | | | | | |
| | (1) Current Tax | 101.13 | 428.46 | 1,226.13 | 4,381.27 | 5,591.47 |
| | (2) Deferred Tax | 334.49 | (47.02) | (412.91) | 345.56 | (516.39) |
| | Total Tax Expense | 435.62 | 381.44 | 813.22 | 4,726.83 | 5,075.08 |
| IX | Profit for the period/year (VII-VIII) | 1,170.99 | 1,048.82 | 1,389.11 | 13,941.10 | 14,201.86 |
| X | Other comprehensive income | | | | | |
| | Items that will not be reclassified to profit or loss | | | | | |
| | (i) Changes in fair value of FVTOCI equity instruments | 328.86 | (163.37) | 31.26 | 407.98 | (30.71) |
| | (ii) Remeasurement of net defined benefit plans | (17.49) | (35.00) | (135.77) | (122.49) | (139.52) |
| | (iii) Share of Other comprehensive income of jointly controlled entity accounted for using equity method | 1.50 | 0.12 | 4.66 | 1.86 | (8.26) |
| | (iv) Income tax relating to these items | (72.60) | 46.83 | 25.72 | (64.70) | 44.35 |
| | Items that will be reclassified to profit or loss | | | | | |
| | (i) Exchange differences in translating the financial statements of foreign operations | - | - | - | - | (0.03) |
| | Other comprehensive income for the period/year (net of tax) | 240.27 | (151.42) | (74.13) | 222.65 | (134.17) |
| XI | Total comprehensive income for the period/year (XI+XII) | 1,411.26 | 897.40 | 1,314.98 | 14,163.75 | 14,067.69 |
| | Profit for the period/year attributable to Owners of the Company | 1,170.99 | 1,048.82 | 1,389.11 | 13,941.10 | 14,201.86 |
| | Profit for the period/year attributable to Non Controlling Interest | - | - | - | - | - |
| | Other comprehensive income attributable to Owners of the Company | 240.27 | (151.42) | (74.13) | 222.65 | (134.17) |
| | Other comprehensive income attributable to Non Controlling Interest | - | - | - | - | - |
| | Total comprehensive income attributable to Owners of the Company | 1,411.26 | 897.40 | 1,314.98 | 14,163.75 | 14,067.69 |
| | Total comprehensive income attributable to Non Controlling Interest | - | - | - | - | - |
| | Paid up equity share capital (Face value ₹10/- each) | 2,909.78 | 2,909.78 | 2,909.78 | 2,909.78 | 2,909.78 |
| | Other Equity | - | - | - | 1,19,131.43 | 1,05,549.60 |
| | Earnings per share (of ₹10 each) | | | | | |
| | (a) Basic | 4.02 | 3.60 | 4.77 | 47.91 | 48.38 |
| | (b) Diluted | 4.02 | 3.60 | 4.77 | 47.91 | 48.38 |
| | (Note: EPS for respective quarters are not annualized) | | | | | |



Rajub

Notes:

- 1 The above Audited Consolidated Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 28, 2026. The auditors of the company have carried out the audit of the same. The Audit Report along with Financial Results for the quarter and year ended March 31, 2026 are available on the Stock Exchanges website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com
 - 2 The above Audited Consolidated Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
 - 3 The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
 - 4 The Board of Directors of Insecticides (India) Limited in its meeting held on August 09, 2024 had approved the dissolution/ liquidation of its wholly owned subsidiary IIL Overseas DMCC, Dubai. IIL Overseas DMCC has filed the windup/ dissolution with DMCCA (Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority) and dissolution is approved vide its letter dated September 19, 2025.
 - 5 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21, 2025. The corresponding all supporting rules under these codes are yet to be notified.
- The Group has estimated that there is no incremental liability due to implications of these laws to the consolidated financial statements.
- Further, the Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 6 The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year up to 31 March 2026 and the unaudited published year-to-date figures up to 31 December 2025 being the date of the end of the third quarter of the financial year which were subjected to a limited review.

Place: Delhi
Date: May 28, 2026

For and on behalf of the Board

Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;

Telefax: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF AUDITED CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2026

| | | (₹ In lacs) | |
|-------|---|--------------------|--------------------|
| S. No | Particulars | As at 31-03-2026 | As at 31-03-2025 |
| | ASSETS | | |
| (1) | Non-current assets | | |
| (a) | Property, plant and equipment | 31,208.52 | 23,119.88 |
| (b) | Capital work-in-progress | 11,856.58 | 15,610.93 |
| (c) | Investment properties | 307.45 | 299.15 |
| (d) | Right-of-use assets | 4,637.00 | 3,904.01 |
| (e) | Other Intangible assets | 803.44 | 863.40 |
| (f) | Intangible assets under development | 1,115.48 | 498.53 |
| (g) | Investment in jointly controlled entity | 1,183.50 | 1,152.37 |
| (h) | Financial assets | | |
| (i) | Investments | 1,230.16 | 822.18 |
| (ii) | Other financial assets | 430.31 | 267.60 |
| (i) | Income tax assets (net) | 501.03 | 152.71 |
| (j) | Other non-current assets | 1,966.29 | 617.01 |
| | Total non-current assets | 55,239.76 | 47,307.77 |
| (2) | Current assets | | |
| (a) | Inventories | 78,021.28 | 88,624.54 |
| (b) | Financial assets | | |
| (i) | Investments | 444.76 | 957.45 |
| (ii) | Trade receivables | 48,697.20 | 38,531.65 |
| (iii) | Cash and cash equivalents | 8,722.64 | 5,592.70 |
| (iv) | Bank balances other than (iii) above | 16.77 | 118.11 |
| (v) | Loans | 26.87 | 25.01 |
| (vi) | Other financial assets | 1,318.15 | 802.47 |
| (c) | Other current assets | 7,530.57 | 7,854.86 |
| | Total current assets | 1,44,778.24 | 1,42,506.79 |
| | Total assets | 2,00,018.00 | 1,89,814.56 |
| | EQUITY AND LIABILITIES | | |
| | EQUITY | | |
| (a) | Equity share capital | 2,909.78 | 2,909.78 |
| (b) | Other equity | 1,19,131.43 | 1,05,549.60 |
| | Total equity | 1,22,041.21 | 1,08,459.38 |
| | LIABILITIES | | |
| (1) | Non-current liabilities | | |
| (a) | Financial liabilities | | |
| (i) | Borrowings | 1,878.23 | 2,347.24 |
| (ii) | Lease liabilities | 900.40 | 264.60 |
| (b) | Provisions | 305.58 | 550.26 |
| (c) | Deferred tax liabilities (Net) | 852.89 | 443.08 |
| | Total non-current liabilities | 3,937.10 | 3,605.18 |
| (2) | Current liabilities | | |
| (a) | Financial liabilities | | |
| (i) | Borrowings | 12,550.44 | 7,614.99 |
| (ii) | Lease liabilities | 375.97 | 239.54 |
| (iii) | Trade Payables | | |
| (A) | total outstanding due of micro enterprises and small enterprises; and | 6,982.87 | 2,268.36 |
| (B) | total outstanding dues of creditors other than micro enterprises and small enterprises. | 36,943.45 | 48,506.08 |
| (iv) | Other financial liabilities | 4,470.98 | 4,692.77 |
| (b) | Other current liabilities | 12,297.27 | 13,064.38 |
| (c) | Provisions | 418.71 | 483.82 |
| (d) | Current tax liabilities (Net) | - | 880.06 |
| | Total current liabilities | 74,039.69 | 77,750.00 |
| | Total equity and liabilities | 2,00,018.00 | 1,89,814.56 |

* Restated

For and on behalf of the Board of Directors
Insecticides (India) Limited



Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Place: Delhi

Date: May 28, 2026

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

AUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

| Particulars | 31-03-2026 | 31-03-2025 |
|---|-------------------|-------------------|
| (₹ in lacs) | | |
| (A) Cash Flow From Operating Activities | | |
| Profit before tax | 18,667.93 | 19,276.94 |
| Adjustment on account of | | |
| - Share of Net Profit of Jointly controlled entity | (29.74) | (57.45) |
| - Depreciation | 3,549.59 | 2,915.34 |
| - (Profit)/ Loss on sale of property, plant & equipment | (44.09) | (19.09) |
| - Net gain on lease modification | (1.56) | - |
| - Interest income | (26.08) | (235.51) |
| - Dividend income | (26.00) | (22.83) |
| - Interest expenses | 1,687.93 | 686.45 |
| - Bad debts written off | 2.85 | 29.26 |
| - Loss Allowance on Advances | 0.17 | 217.83 |
| - Provision for impairment of trade receivables | 446.75 | 554.65 |
| - Gain on investment | (24.82) | (5.16) |
| - Derivative (gain) / loss | (867.24) | 270.90 |
| - Liabilities written back | (5.80) | - |
| - Unrealised exchange differences | 318.16 | (290.15) |
| Operating Profit Before Working Capital Changes | 23,648.05 | 23,321.18 |
| Adjustments for | | |
| - (Increase)/Decrease in security deposits | (50.48) | (30.72) |
| - (Increase)/Decrease in inventories | 10,603.27 | (7,886.27) |
| - (Increase)/Decrease in trade receivables | (10,126.84) | (9,398.04) |
| - (Increase)/Decrease in loans | (1.86) | (10.62) |
| - (Increase)/Decrease in other financial assets | (524.11) | (714.74) |
| - (Increase)/Decrease in other current/ non-current assets | 334.84 | 398.40 |
| - Increase/(Decrease) in provisions | (432.28) | 264.94 |
| - Increase/(Decrease) in trade payables | (7,476.68) | 9,105.41 |
| - Increase/(Decrease) in other financial liabilities | 427.02 | (295.22) |
| - Increase/(Decrease) in other current liabilities | (767.10) | (1,228.40) |
| Cash generated from operations | 15,633.83 | 13,525.92 |
| Less: Income tax paid | (5,609.19) | (4,180.23) |
| Net cash flow (used in) / from operating activities (A) | 10,024.64 | 9,345.69 |
| (B) Cash Flow From Investing Activities | | |
| - Purchase of property, plant and equipment and intangible assets, capital-work-in-progress and intangible assets under development | (9,459.17) | (3,728.90) |
| - Proceeds from sale of property plant and equipment | 203.46 | 261.87 |
| - Interest received | 26.08 | 235.51 |
| - Proceeds from / (investment in) bank deposits (net) | (10.89) | 2.31 |
| - Purchase of investment | - | (804.85) |
| - Sale of investment | 558.88 | 239.86 |
| - Dividends received | 34.42 | 22.17 |
| Net cash flow (used in) / from Investing Activities (B) | (8,647.22) | (3,772.03) |
| (C) Cash Flow From Financing Activities | | |
| - Repayment due to Buyback of equity shares including premium, expenses & taxes | - | (6,188.02) |
| - Repayment of non-current borrowings | (1,327.58) | (1,331.12) |
| - Proceeds from non-current borrowings | 799.86 | 708.59 |
| - Proceeds/(Repayment) from/of current borrowings | 4,822.04 | 2,212.25 |
| - Payment of lease liabilities | (279.00) | (220.41) |
| - Interest paid | (1,680.84) | (698.55) |
| - Dividend paid (Final & Interim) | (581.96) | (591.96) |
| Net cash flow (used in) / from financing activities (C) | 1,752.52 | (6,109.22) |
| Net increase/ (decrease) in Cash and Cash Equivalents (A+B+C) | 3,129.94 | (535.56) |
| Cash and Cash Equivalents at the beginning of the year | 5,592.70 | 6,128.26 |
| Cash and Cash Equivalents at the end of the year | 8,722.64 | 5,592.70 |

* Restated

For and on behalf of the Board of Directors
Insecticides (India) Limited



Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Place: Delhi
Date: May 28, 2026

Independent Auditor's Report on the Quarterly and Year ended Audited Consolidated Financial Results of Insecticides (India) Limited Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

To
**The Board of Directors of
Insecticides (India) Limited**

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date Consolidated Financial Results of **Insecticides (India) Limited** (hereinafter referred to as the "the Parent or the Company"), its subsidiaries (Parent Company and its subsidiaries together referred to as "the Group") and its share of net profit/(loss) after tax and total comprehensive income/(loss) of its jointly controlled entity for the quarter and year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial statements/financial information of a subsidiaries and its jointly controlled entity referred to in Other Matters section below, **the Statement:**

- a. includes the results of the following entities:

Parent

- Insecticides (India) Limited

Jointly Controlled Entity

- OAT & IIL India Laboratories Private Limited

Subsidiary

- IIL Biologicals Limited
- Kaeros Research Limited (formerly known as Kaeros Research Private Limited)
- IIL Overseas DMCC (dissolved w.e.f 19.09.2025)

- b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income/(loss) and other financial information of the Group for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Consolidated Financial Results' section of our report. We are independent of the Group and its jointly controlled entity in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit



of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Managements and those charge with governance for the Consolidated Financial Results

The Statement, which is the responsibility of the Parent Company's management and has been approved by the Parent Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Parent Company's Board of Directors are responsible for the preparation and presentation of the statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group and its jointly controlled entity in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and its jointly controlled entity, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group and its jointly controlled entity and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been used for the purpose of preparation of the Statement by the Directors of the Parent Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its jointly controlled entity are responsible for assessing the ability of the Group and of its jointly controlled entity to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its jointly controlled entity are responsible for overseeing the financial reporting process of their respective companies.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Parent company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and of its jointly controlled entity to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its jointly controlled entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entity within the Group and of its jointly controlled entity of which we are the independent auditors and whose financials information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entity included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Parent Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

1. The accompanying Statement includes the audited financial statements, in respect of:

- (a) 2 subsidiaries, whose audited financial statement reflects total assets of Rs. 5,618.00 lakhs as at March 31, 2026, total revenue of Rs. 2931.60 Lakhs and Rs. 11,664.37 Lakhs, total net profit/(loss) after tax of Rs. (76.03) lakhs and Rs. 459.65 lakhs, total comprehensive income/(loss) of Rs. (76.34) lakhs and Rs. 459.35 Lakhs for the quarter and year ended March 31, 2026 respectively and net cash flows of Rs. (44.56) lakhs for the year ended on that date, as considered in the Statement which have been audited by one of the joint auditor, individually.



**S S KOTHARI MEHTA
& CO. LLP**

Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi - 110020

DEVESH PAREKH & CO.

Chartered Accountants
675, Aggarwal Cyber Plaza-2,
Netaji Subhash Place, Pitampura, Delhi-110034

- (b) The Statement includes the Parent Company's share of net profit/(loss) after tax of Rs. (50.12) lakhs and Rs. 29.74 lakhs and total comprehensive income/(loss) of Rs. (49.00) lakhs and Rs. 31.13 lakhs for the quarter and year ended March 31, 2026, respectively, as considered in the statement, in respect of jointly controlled entity. These financial statements are audited by other auditors.

The reports on the audited financial statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of subsidiary and jointly controlled entity, is based solely on the reports of such auditors and the procedures performed by us are as stated under Auditor's Responsibilities for the Audit of the Statement section above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of such auditors.

2. The wholly owned foreign subsidiary of the Company, IIL Overseas DMCC (Dubai) was dissolved with effect from September 19, 2025. Further, there were no operation in this subsidiary from April 01, 2025 until the date of dissolution i.e. September 19, 2025 (Refer note no. 4 of the statement). Therefore, the statement does not include any financial results of this subsidiary in the unaudited consolidated financial results for the quarter ended March 31, 2026 and for the period April 01, 2025 to March 31, 2026.

According to the information and explanations given to us by the Management, these financial results are not material to the group.

Our conclusion on the statement is not modified in respect of the above matters.

3. The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the end of third quarter of the current financial year, which were subjected to limited review by us, as required under the listing Regulations.

For S S Kothari Mehta & Co. LLP

Chartered Accountants

Firm's registration number: 000756N/N500441



Vijay Kumar
Partner

Membership number: 092671

UDIN : 26092671CEBSOP5279

Place: Delhi


Date : 28th May 2026



For Devesh Parekh & Co.

Chartered Accountants

Firm's registration number: 013338N



Meenakshi
Partner

Membership number: 527873

UDIN: 26527873YFBRLF9484

Place: Delhi

Date : 28th May 2026



Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi -110 033
Telefax : + 91 11 27679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



insecticides
(INDIA) LIMITED

Ref : IIL/SE/2026/2805/02

Dated : May 28, 2026

The Manager

| | |
|---|---|
| Listing Compliance Department BSE Limited (Through BSE Listing Centre) | Listing Compliance Department National Stock Exchange of India Limited (Through NEAPS) |
| Scrip Code: 532851 | Symbol: INSECTICID |

Dear Sir/Madam,

Sub: Declaration on the Auditor's Report with Unmodified opinion under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, Sandeep Kumar Aggarwal, Chief Financial Officer of the Company, in compliance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, hereby declare that Joint Statutory Auditors of the Company i.e. S S Kothari Mehta & Co., LLP (Firm Registration No. 000756N) and Devesh Parekh & Co., (Firm Registration No. 013338N) have issued the Audit report with unmodified opinion in respect of the Audited Financial Results (Standalone and Consolidated) of the Company for the Financial Year ended on March 31, 2026.

This is for your information on records.

Thanking you,

Yours Truly,

For Insecticides (India) Limited

(Sandeep Aggarwal)

Chief Financial Officer

Mem No.: 90189



Annexure-II

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular bearing Ref. No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

The terms of the Scheme, inter-alia, are as under:

| S. No. | Particulars | Description |
|--------|---|---|
| 1. | Name of the Scheme | Insecticides (India) Limited Employees Stock Purchase Scheme 2026 (<i>"IIL ESPS Scheme 2026 or Scheme"</i>) |
| 2. | Brief details of options granted | The IIL ESPS Scheme 2026 is implemented through to extend the benefits to the eligible Employees in terms of the Scheme. However, no offer has been made under the Scheme, as on date. |
| 3. | Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable) | Yes |
| 4. | Total number of shares covered by these Options | The maximum number of Shares that may be offered, issued and allotted under the Scheme shall not exceed 2,00,000 (Two Lakhs) fully paid-up Shares of face value Rs. 10/- each. |
| 5. | Pricing formula | Under this Scheme, the Offer Price will be decided by the Committee based on Market Price of Company, which shall be intimated by the Company through offer letter. The Committee shall provide a discount on such price as arrived above, as deems fit. However, in any case the Offer Price shall not go below the face value of Share of the Company. |
| 6. | Options vested | Not Applicable. |
| 7. | Time within which option may be exercised | The Offer can be subscribed, either wholly or partly, by submitting the prescribed written/electronic subscription application to the Committee or any of its authorized |



| | | |
|-----|---|--|
| | | representatives, along with the Offer Price, applicable tax and other charges, if any, within such time period as mentioned under the Offer Letter. |
| 8. | Options exercised Shares Subscribed | Not Applicable, as this outcome is pertaining to date of approval of the Scheme by the Board of Directors. |
| 9. | Money realized by exercise of Options -subscription of offer | |
| 10. | The total number of Shares arising as a result of Offer | |
| 11. | Options -Offers lapsed | |
| 12. | Variation in terms of Offer Options | |
| 13. | Brief details of significant terms | <p>The Scheme is administered by the Nomination Remuneration and Ethics Committee ("NRC Committee").</p> <p>The Committee may make an Offer to one or more eligible Employees, in accordance with the terms and conditions of the Scheme for the time being in force, and subject to Employee's employment terms or his continuity in the employment or any other factors as set out by the Committee.</p> <p>The Offer can be subscribed, either wholly or partly, by submitting the prescribed written/electronic subscription application to the Committee or any of its authorized representatives, along with the Offer Price, applicable tax and other charges, if any, within such time period as mentioned under the Offer Letter.</p> <p>Under this Scheme, the Offer Price will be decided by the Committee based on Market Price of Company, which shall be intimated by the Company through offer letter. However, the Offer Price shall not go below the face value of Share of the Company.</p> |

Regd. & Corporate Office : 401-402, Lusa Tower
 Azadpur Commercial Complex, Delhi -110 033
 Telefax : +91 1127679700-05 (6 Lines)
 e mail : info@insecticidesindia.com
www.insecticidesindia.com
 CIN : L65991DL1996PLC083909



insecticides
 (INDIA) LIMITED

| | | |
|-----|--|--|
| 14. | Subsequent changes or cancellation or subscription of offers. exercise of such Options. | Not Applicable, as this outcome is pertaining to date of approval of the Scheme by the Board of Directors. |
| 15. | Diluted earnings per share pursuant to the issue of equity shares under Offer. | |



Annexure-III

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2 / I/3762/2026 dated January 30, 2026

| S. No. | Disclosure Requirement | Details |
|--------|---|---|
| 1 | Name | Mrs. Nikunj Aggarwal (DIN: 06569091) |
| 2 | Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise | Resignation of Mrs. Nikunj Aggarwal (DIN: 06569091) as the Whole-Time Director of the Company with immediate effect i.e. May 28, 2026 |
| 3 | Date of appointment/re-appointment /cessation (as applicable) & Terms of appointment/re-appointment | Resigned with immediate effect i.e. May 28, 2026 |
| 4 | Brief profile (in case of appointment); | Not Applicable |
| 5 | Disclosure of relationships between directors (in case of appointment of a director). | Not Applicable |

Date: May 28, 2026

To,
The Board of Directors
Insecticides (India) Limited

Subject: Resignation from the position of Whole- Time Director of Insecticides (India) Limited

Dear Sir/Madam,

I, Nikunj Aggarwal (DIN: 06569091), hereby tender my resignation from the position of Whole Time Director (WTD) of Insecticides (India) Limited, with immediate effect to pursue my personal interests. It's been an honour and privilege to serve as the WTD and contribute to growth and success during my tenure.

I hereby confirm that there are no other material reasons for my resignation other than those stated above.

I'll be grateful for the trust and confidence reposed in me by the Board and thank the entire Board for their unwavering support throughout my tenure as Whole Time Director of the Company.

I kindly request the Management to take note of my resignation and complete all necessary intimations, filings, and disclosures with the concerned statutory and regulatory authorities, as may be required under applicable laws.

Thanking you.
Yours faithfully,



Nikunj Aggarwal
Whole- Time Director
DIN: 06569091
Insecticides (India) Limited

Received on
28/05/2026
Sd/- P. L. S.
Approved & Relive
Nikunj





Annexure-IV

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2 / I/3762/2026 dated January 30, 2026

1. Mr. Atul Kumar- VP Sales (North)

| S. No. | Particulars | Description |
|--------|--|--|
| 1. | Name | Mr. Atul Kumar |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Mr. Atul Kumar appointed as Vice President-Sales (North), Senior Management Personnel (SMP) of the Company |
| 3. | Date of appointment/ cessation (as applicable) & Term of appointment | w.e.f. May 28, 2026 |
| 4. | Brief profile (in case of appointment); | <p>Mr. Atul Kumar is a seasoned professional with over 30 years of extensive experience in Sales & Marketing, having held leadership roles with organization such as DuPont and Dhanuka Agritech. By qualification, he has a Degree in M.Sc. in Agriculture from Punjab Agriculture University.</p> <p>His core strengths include Sales & Marketing, Market penetration strategies, Product lifecycle management, Pricing strategies, Risk Assessment and Mitigation, Budgeting and Forecasting Customer relationship management, Business development and growth.</p> |
| 5. | Disclosure of relationships between directors (in case of appointment of a director). | Not Applicable. |



insecticides
(INDIA) LIMITED

2. Mr. Sanskar Aggarwal- Whole Time Director (Additional)

| S. No. | Particulars | Description |
|--------|--|--|
| 1. | Name | Mr. Sanskar Aggarwal (DIN: 09675297) |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Mr. Sanskar Aggarwal (DIN: 09675297) appointed as Whole Time Director (Additional) of the Company and as Director (Additional) in Kaeros Research Limited <i>-formerly known as Kaeros Research Private Limited</i> (a Wholly owned subsidiary) |
| 3. | Date of appointment/ cessation (as applicable) & Term of appointment | w.e.f. May 28, 2026 |
| 4. | Brief profile (in case of appointment); | <p>Mr. Sanskar Aggarwal (DIN: 09675297), born into a family of passionate leader, joined his family business, IIL, after completing his graduation from the United States. With a global perspective and deep-rooted commitment to Indian agriculture, Sanskar ji envisions delivering complete, integrated solutions to farmers, addressing their evolving needs through innovation and accessibility.</p> <p>Over the past four years, even before formally taking charge, Sanskar ji has been the driving force behind IIL's technological transformation, playing a key role in introducing cutting-edge advancements aimed at improving productivity. His strategic approach blends modern agri-tech solutions with grassroots-level understanding, positioning IIL as a forward-thinking, farmer-first organization.</p> |

Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi-110 033
Telefax : +91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



| | | |
|----|---|--|
| | | His core strengths include Visionary Leadership with Global Perspective, Strategic Marketing & Sales Acumen, Technology-Driven Transformation, Innovation & Future Readiness, Farmer-First Approach. |
| 5. | Disclosure of relationships between directors (in case of appointment of a director). | Son of Mr. Rajesh Kumar Aggarwal, Managing Director and Mrs. Nikunj Aggarwal, Whole Time Director, Grandson of Mr. Hari Chand Aggarwal, Chairman & Whole Time Director and not related to any other Director / Key Managerial Personnel. |
| 6. | Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-2019 and National Stock Exchange of India Ltd. ref. no. NSE/CML/2018/24 dated 20 th June, 2018. | Mr. Sanskar Aggarwal (DIN: 09675297), is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. |



Annexure-V

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2 / I/3762/2026 dated January 30, 2026

| S. No. | Disclosure Requirement | Details |
|--------|--|---|
| 1 | Name | M/s. T Jain & Associates, Chartered Accountants (FRN:017110C) |
| 2 | Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise | Appointment |
| 3 | Date of appointment/re-appointment/cessation (as applicable) & Terms of appointment/re-appointment | Appointed as an Internal Auditor of the Company for a period of five years w.e.f April 01, 2026 till March 31, 2031. |
| 4 | Brief profile (in case of appointment); | M/s. T Jain & Associates is having an experience in fields of direct and indirect tax, internal audit, risk advisory, IFC review, investigation, Due-diligence, banking audits & compliance monitoring etc. |
| 5 | Disclosure of relationships between directors (in case of appointment of a director). | Not Applicable |